Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Metoprolol succinate sustained-release capsule and preparation method

A technology of metoprolol succinate and sustained-release capsules is applied in the directions of non-active ingredients medical preparations, active ingredients-containing medical preparations, pharmaceutical formulas, etc. , good operability and reproducibility, stable drug release effect

Active Publication Date: 2013-03-13
佛山市隆信医药科技有限公司
View PDF6 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0011] In the technology disclosed above, the drug dose of the matrix tablet is relatively concentrated, which is easily affected by factors such as the human gastrointestinal tract and food, resulting in large differences.
And what adopted in the technology of micropill is the method for adding medicine to the blank ball core, and the process is complicated, so a kind of preparation process is simple, and the preparation process of metoprolol succinate with stable drug release is needed

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Metoprolol succinate sustained-release capsule and preparation method
  • Metoprolol succinate sustained-release capsule and preparation method
  • Metoprolol succinate sustained-release capsule and preparation method

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0044] see figure 1 , the preparation method of the sustained-release capsules of metoprolol succinate of the present invention comprises the steps:

[0045] 1) preparing a pill core containing medicine;

[0046] 2) preparing coating solution;

[0047] 3) A slow-release coating layer is included;

[0048] 4) aging;

[0049] 5) making capsules;

[0050] Wherein, step 1) and step 2) have no sequence.

Embodiment 1

[0052] The sustained-release capsule of metoprolol succinate of the present embodiment is made of capsule shell and its contents, and the content comprises metoprolol succinate sustained-release pellets, and the sustained-release pellets of metoprolol succinate include succinate The metoprolol succinate-containing pill core and the slow-release coating layer covering the metoprolol succinate-containing pill core.

[0053] Among them, the drug-containing pill core is made of metoprolol succinate as an active ingredient, microcrystalline cellulose and lactose as fillers, and PVPK30 aqueous solution as a binder. Wherein, by weight, metoprolol succinate, microcrystalline cellulose and lactose are respectively 47.5 parts, 55 parts and 55 parts. In other embodiments, the weight ratio of microcrystalline cellulose and lactose may also be 1:2 or 2:1 or 1:1.5.

[0054] Wherein, by weight, the slow-release coating layer is made of 250 parts of Eudragit NE30D, 60 parts of talcum powder,...

Embodiment 2

[0075] The sustained-release capsule of metoprolol succinate of the present embodiment is made of capsule shell and its contents, and the content comprises metoprolol succinate sustained-release pellets, and the sustained-release pellets of metoprolol succinate include succinate The metoprolol succinate-containing pill core and the slow-release coating layer covering the metoprolol succinate-containing pill core.

[0076] Wherein, the drug-containing pill core is made of metoprolol succinate as an active ingredient, microcrystalline cellulose, lactose, and starch as fillers, and 4% by mass of HPMC solution as a binding agent. Wherein, by weight, metoprolol succinate, microcrystalline cellulose, lactose and starch are respectively 55 parts, 35 parts, 70 parts and 30 parts.

[0077] Wherein, by weight, the slow-release coating layer is made of 200 parts of Surelease (water dispersion of ethyl cellulose), 5 parts of talcum powder and 70 parts of water.

[0078] The preparation m...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a metoprolol succinate sustained-release capsule, consisting of a capsule shell and contents; the contents comprise a metoprolol succinate sustained-release pellet; the metoprolol succinate sustained-release pellet comprises a metoprolol succinate contained pill core and a sustained-release coating layer coated outside the metoprolol succinate contained pill core; the metoprolol succinate contained pill core is prepared by using metoprolol succinate as the active ingredient and mixing with an auxiliary material, wherein the weight ratio of the metoprolol succinate to the auxiliary material is 1:1.5 to 1:3. The metoprolol succinate sustained-release medicine disclosed by the invention is stable and the expected effects of all release behaviors in acid, alkaline and water can be achieved. The invention further discloses a method for preparing the metoprolol succinate sustained-release capsule; compared with the prior art, the process is simpler and has good operability and reproducibility.

Description

technical field [0001] The invention relates to the technical field of preparations of metoprolol succinate, in particular to a slow-release capsule of metoprolol succinate and a preparation method thereof. Background technique [0002] With the development of society and the continuous improvement of people's living standards, the prevalence of various cardiovascular diseases is on the rise. According to the survey in 2002, the prevalence rate of hypertension among Chinese adults is 18.8%, and the number of people suffering from hypertension is at least 200 million. In addition, the incidence of coronary heart disease and arrhythmia is also increasing year by year. Prevention and treatment of hypertension, coronary heart disease, arrhythmia, etc. have become long-term tasks of medical and health work. [0003] Metoprolol is a selective β1 receptor blocker, which is one of the commonly used drugs for the treatment of hypertension, coronary heart disease, chronic heart fail...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K9/52A61K31/138A61K47/38A61K47/36A61K47/32A61P9/12A61P9/10A61P9/06A61P9/04
Inventor 陈华兆黎炜烘黎秉富曲金栋
Owner 佛山市隆信医药科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com